1Levy ID,Garrison RJ,Savage DD,et al.Prognostic implications of echocardiographically determined left ventriculai mass in the Framingham heart study[J].N Engl J Med,1990,322:1561-1566.
2Rossow CF,Minami E,Chase EG,et al.NFATc3-induced reductions in voltage-gated K^+ currents after myocardial infarction[J].Circ Res,2004,94:1340 -1350.
3Huang B,Qin D,EI-Sherif N.Early down-regulation of K^+ channel genes and currents in the postinfarction heart[J].J Cardiovasc Electrophysiol,2000,11:1252 -1261.
4Akhter SA,Luttrell LM,Rockman HA,et al.Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy[J].Science,1998,280:574-577.
5van Rooij E,Doevendans PA,Crijns HJ,et al.MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction[J].Circ Res,2004,94:e18 -26.
6Esposito G,Rapacciuolo A,Naga Prasad Sv,et al.Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress[J].Circulation,2002,105:85-92.
7Hill JA,Rothermel B,Yoo KD,et al.Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy:preservation of systolic function[J].J Biol Chem,2002,277:10251-10255.
8Booz GW.Putting the brakes on cardiac hypertrophy:exploiting the NO-cGMP counter-regulatory system[J].Hypertension,2005,45:341-346.
9Wilkins BJ,Molkentin JD.Calcineurin and cardiac hypertrophy:where have we been? Where are we going?[J].J physiol,2002,541:1 -8.
10Frey N,Katus HA,Olson EN,et al.Hypertrophy of the heart:a new therapeutic target[J].Circulation,2004,109:1580-1589.
2Jin K, Graham SH, Mao X, et al. Fas (CD95) may mediate delayed cell death in hippocampal CA1 sector after global ischemia [ J ]. J Cereb Blood Flow Metab ,2001,21(12) :1411 - 1421.
3Liu S, Khemlani LS, Shapiro RA, et al. Expression of CD14 by hepatocytes: upregulation by cytokines during endotoxemia [ J ]. Infect Immun, 1998,66 ( 11 ): 5089 -5098.
4Asai A, Qiu J, Narita Y, et al. High level calcineurin activity predisposes neuronal cells to apoptosis [ J ]. J Biol Chem, 1999,274 (48): 34450 - 34458.
5Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-kappaB activity [J]. Annu Rev Immunol, 2000,18:621 - 663.
6Mattson MP, Culmsee C, Yu Z, et al. Roles of nuclear factor kappaB in neuronal survival and plasticity [ J ]. J Neurochem, 2000,74 (2) :443 - 456.
7Koulich E, Nguyen T, Johnson K, et al. NF-kappa B is involved in the survival of cerebellar granule neurons:association of I kappa B beta phosphorylation with cell survival [J]. J Neurochem, 2001,76(4) :1188 - 1198.
8Jarosinski KW, Whitney LW, Massa PT. Specific deficiency in nuclear factor-kappa B activation in neurons of the central nervous system [J]. Lab Invest, 2001,81(9) :1275 - 1288.
9Wood AM, Bristow DR. N-Methyl-D-aspartate receptor desensitisation is neuroprotective by inhibiting glutamateinduced apoptotic-like death [ J ]. J Neurochem, 1998,70(2) :677 -687.
8Kincaid RL, Balaban CD, Billingsley ML. Differential localization of calmodulin-dependent enzymes in rat brain: evidence for selective expression of cyclic nucleotide phosphodiestrase in specific neurons [ J ]. Proc Natl Acad Sci USA, 1987,84:1118- 1122.
9Wang HG, Pathan N, Ethell IM, et al. Ca^2+ -induced apoptosis through calcineurin dephosphorylation of BAD [ J ]. Science, 1999,284:339 - 343.
10Uchino H, Minamikawa-Tachino R, Kristian T, et al. Differential neuroproteetion by cyclosporin A and FKS06 following isehemia corresponds with differing abilities to inhibit calcineurin and the mitochondrial permeability transition [J]. Neurobiol Dis, 2002,10:219-233.
